These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 21801083)

  • 1. Practical guidance for prescribing ziprasidone in acute manic or mixed episodes of bipolar I disorder.
    Cañas F; Correll CU; Fagiolini A; Larmo I; Levy P; Papageorgiou G; Rossi A; Zink M; Montes JM
    Expert Opin Pharmacother; 2011 Oct; 12(14):2245-63. PubMed ID: 21801083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies for successful clinical management of schizophrenia with ziprasidone.
    Fagiolini A; Cañas F; Gallhofer B; Larmo I; Levy P; Montes JM; Papageorgiou G; Zink M; Rossi A
    Expert Opin Pharmacother; 2010 Sep; 11(13):2199-220. PubMed ID: 20658947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral ziprasidone in the treatment of patients with bipolar disorders: a critical review.
    Sacchetti E; Galluzzo A; Valsecchi P
    Expert Rev Clin Pharmacol; 2011 Mar; 4(2):163-79. PubMed ID: 22115400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ziprasidone for the treatment of acute manic or mixed episodes associated with bipolar disorder.
    Warrington L; Lombardo I; Loebel A; Ice K
    CNS Drugs; 2007; 21(10):835-49. PubMed ID: 17850172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ziprasidone in bipolar disorder.
    Versiani M
    Expert Opin Pharmacother; 2006 Jun; 7(9):1221-8. PubMed ID: 16732708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid antipsychotic response with ziprasidone predicts subsequent acute manic/mixed episode remission.
    Ketter TA; Agid O; Kapur S; Loebel A; Siu CO; Romano SJ
    J Psychiatr Res; 2010 Jan; 44(1):8-14. PubMed ID: 19699488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The factor structure of clinical symptoms in mixed and manic episodes prior to and after antipsychotic treatment.
    Harvey PD; Endicott JM; Loebel AD
    Bipolar Disord; 2008 Dec; 10(8):900-6. PubMed ID: 19594505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using oral ziprasidone effectively: the food effect and dose-response.
    Citrome L
    Adv Ther; 2009 Aug; 26(8):739-48. PubMed ID: 19669631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ziprasidone for maintenance treatment of bipolar I disorder in adults.
    Dubovsky SL; Dubovsky AN
    Expert Opin Pharmacother; 2011 Apr; 12(5):817-24. PubMed ID: 21385150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the pharmacokinetics, safety and clinical efficacy of ziprasidone for the treatment of schizophrenia and bipolar disorder.
    Mandrioli R; Protti M; Mercolini L
    Expert Opin Drug Metab Toxicol; 2015 Jan; 11(1):149-74. PubMed ID: 25483358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophrenia.
    Gao K; Pappadopulos E; Karayal ON; Kolluri S; Calabrese JR
    J Clin Psychopharmacol; 2013 Jun; 33(3):425-31. PubMed ID: 23609405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study.
    Vieta E; Ramey T; Keller D; English PA; Loebel AD; Miceli J
    J Psychopharmacol; 2010 Apr; 24(4):547-58. PubMed ID: 19074536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ziprasidone HCl capsules for the adjunctive maintenance treatment of bipolar disorder in adults.
    Citrome L
    Expert Rev Neurother; 2010 Jul; 10(7):1031-7. PubMed ID: 20586686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aripiprazole for the treatment of bipolar disorder: a review of current evidence.
    Fagiolini A; Nitti M; Forgione RN; Marra FS; Casamassima F
    Expert Opin Pharmacother; 2011 Feb; 12(3):473-88. PubMed ID: 21254952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder.
    Suppes T; Eudicone J; McQuade R; Pikalov A; Carlson B
    J Affect Disord; 2008 Apr; 107(1-3):145-54. PubMed ID: 17904226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials.
    Greenberg WM; Citrome L
    CNS Drug Rev; 2007; 13(2):137-77. PubMed ID: 17627670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study.
    Lee HB; Yoon BH; Kwon YJ; Woo YS; Lee JG; Kim MD; Bahk WM
    Clin Drug Investig; 2013 Oct; 33(10):743-53. PubMed ID: 23990283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug safety evaluation of ziprasidone.
    Citrome L
    Expert Opin Drug Saf; 2011 May; 10(3):437-48. PubMed ID: 21332416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly patients: retrospective findings from a psychiatric emergency service.
    Kohen I; Preval H; Southard R; Francis A
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):240-5. PubMed ID: 16503319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder.
    DelBello MP; Versavel M; Ice K; Keller D; Miceli J
    J Child Adolesc Psychopharmacol; 2008 Oct; 18(5):491-9. PubMed ID: 18928413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.